{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:58:19Z","timestamp":1778803099931,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40120-022-00388-y","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:49:18Z","timestamp":1659113358000},"page":"1571-1582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Screening, Diagnosis, and Management of Parkinson\u2019s Disease Psychosis: Recommendations From an Expert Panel"],"prefix":"10.1007","volume":"11","author":[{"given":"Rajesh","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary W.","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasar","family":"Torres-Yaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"issue":"5","key":"388_CR1","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/j.1582-4934.2011.01311.x","volume":"16","author":"KA Jellinger","year":"2012","unstructured":"Jellinger KA. Cerebral correlates of psychotic syndromes in neurodegenerative diseases. J Cell Mol Med. 2012;16(5):995\u20131012.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"388_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996\u20131001.","journal-title":"Arch Neurol"},{"issue":"1","key":"388_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00702-015-1400-x","volume":"123","author":"J Levin","year":"2016","unstructured":"Levin J, Hasan A, Hoglinger GU. Psychosis in Parkinson\u2019s disease: identification, prevention and treatment. J Neural Transm (Vienna). 2016;123(1):45\u201350.","journal-title":"J Neural Transm (Vienna)"},{"key":"388_CR4","first-page":"3256542","volume":"2017","author":"RN Taddei","year":"2017","unstructured":"Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of psychosis in Parkinson\u2019s disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons Dis. 2017;2017:3256542.","journal-title":"Parkinsons Dis"},{"issue":"6","key":"388_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/mds.22839","volume":"25","author":"G Fenelon","year":"2010","unstructured":"Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763\u20136.","journal-title":"Mov Disord"},{"issue":"3","key":"388_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11940-013-0281-2","volume":"16","author":"JG Goldman","year":"2014","unstructured":"Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson\u2019s disease. Curr Treat Options Neurol. 2014;16(3):281.","journal-title":"Curr Treat Options Neurol"},{"issue":"6","key":"388_CR7","first-page":"368","volume":"42","author":"MP Cruz","year":"2017","unstructured":"Cruz MP. Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson\u2019s disease. P T. 2017;42(6):368\u201371.","journal-title":"P T"},{"key":"388_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2022.2058406","author":"M Sabbagh","year":"2022","unstructured":"Sabbagh M, Small GW, Isaacson SH, Torres-Yaghi Y, Pagan F, Pahwa R. Unmet needs in the diagnosis and treatment of Parkinson\u2019s disease psychosis and dementia-related psychosis. Int J Psychiatry Clin Pract. 2022. https:\/\/doi.org\/10.1080\/13651501.2022.2058406.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"2","key":"388_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398.","journal-title":"Mov Disord"},{"key":"388_CR10","doi-asserted-by":"publisher","first-page":"4938154","DOI":"10.1155\/2016\/4938154","volume":"2016","author":"N Divac","year":"2016","unstructured":"Divac N, Stojanovic R, Savic Vujovic K, Medic B, Damjanovic A, Prostran M. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson\u2019s disease. Behav Neurol. 2016;2016:4938154.","journal-title":"Behav Neurol"},{"issue":"11","key":"388_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ptdy.2019.10.022","volume":"25","author":"DR Fixen","year":"2019","unstructured":"Fixen DR. 2019 AGS Beers Criteria for older adults. Pharm Today. 2019;25(11):42\u201354.","journal-title":"Pharm Today"},{"issue":"9916","key":"388_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340.","journal-title":"Lancet"},{"key":"388_CR13","unstructured":"NUPLAZID\u2122 (pimavanserin) [package insert]. San Diego: ACADIA Pharmaceuticals; 2016."},{"key":"388_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.parkreldis.2020.06.026","volume":"77","author":"CG Ballard","year":"2020","unstructured":"Ballard CG, Kreitzman DL, Isaacson S, et al. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord. 2020;77:100\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"388_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.parkreldis.2021.04.012","volume":"87","author":"SH Isaacson","year":"2021","unstructured":"Isaacson SH, Ballard CG, Kreitzman DL, et al. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson\u2019s disease psychosis patients. Parkinsonism Relat Disord. 2021;87:25\u201331.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"388_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Parkinson Study Group","year":"1999","unstructured":"Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340(10):757\u201363.","journal-title":"N Engl J Med"},{"issue":"5","key":"388_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo-controlled study with open follow-up. J Neurol Neurosurg Psychiatry. 2004;75(5):689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"388_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/0891988716640378","volume":"29","author":"P Desmarais","year":"2016","unstructured":"Desmarais P, Massoud F, Filion J, Nguyen QD, Bajsarowicz P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J Geriatr Psychiatry Neurol. 2016;29(4):227\u201336.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"388_CR19","unstructured":"Schleisman A. Treatment of Parkinson\u2019s disease psychosis; 2016. https:\/\/www.uspharmacist.com\/article\/treatment-of-parkinsons-disease-psychosis."},{"issue":"15","key":"388_CR20","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","journal-title":"Mov Disord"},{"issue":"1","key":"388_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mds.27862","volume":"35","author":"KR Chaudhuri","year":"2020","unstructured":"Chaudhuri KR, Schrag A, Weintraub D, et al. The Movement Disorder Society Nonmotor Rating Scale: initial validation study. Mov Disord. 2020;35(1):116\u201333.","journal-title":"Mov Disord"},{"issue":"13","key":"388_CR22","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901\u201311.","journal-title":"Mov Disord"},{"issue":"7","key":"388_CR23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 2006;21(7):916\u201323.","journal-title":"Mov Disord"},{"issue":"3","key":"388_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.parkreldis.2012.10.022","volume":"19","author":"T Voss","year":"2013","unstructured":"Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened scale for assessment of positive symptoms for Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord. 2013;19(3):295\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"388_CR25","unstructured":"Andreasen NC. The Scale for Assessment of Positive Symptoms (SAPS); 1984. https:\/\/web.archive.org\/web\/20101228020846\/http:\/\/www.movementdisorders.org\/UserFiles\/file\/Long_SAPS_2000_publish%281%29.pdf."},{"issue":"7","key":"388_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","volume":"66","author":"JM Miyasaki","year":"2006","unstructured":"Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996\u20131002.","journal-title":"Neurology"},{"issue":"10","key":"388_CR27","doi-asserted-by":"publisher","first-page":"898.e1\u2013e7","DOI":"10.1016\/j.jamda.2015.06.021","volume":"16","author":"C Ballard","year":"2015","unstructured":"Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898.e1-e7.","journal-title":"J Am Med Dir Assoc"},{"issue":"2","key":"388_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/mdc3.12139","volume":"2","author":"JM Shine","year":"2015","unstructured":"Shine JM, Mills JMZ, Qiu J, et al. Validation of the psychosis and hallucinations questionnaire in non-demented patients with Parkinson\u2019s disease. Mov Disord Clin Pract. 2015;2(2):175\u201381.","journal-title":"Mov Disord Clin Pract"},{"issue":"9","key":"388_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s00415-005-0816-x","volume":"252","author":"D Brandstaedter","year":"2005","unstructured":"Brandstaedter D, Spieker S, Ulm G, et al. Development and evaluation of the Parkinson Psychosis Questionnaire: a screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson\u2019s disease. J Neurol. 2005;252(9):1060\u20136.","journal-title":"J Neurol"},{"issue":"8","key":"388_CR30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061\u20138.","journal-title":"Mov Disord"}],"updated-by":[{"DOI":"10.1007\/s40120-023-00507-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00388-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T12:51:50Z","timestamp":1688647910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00388-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00388-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40120-023-00507-3","asserted-by":"object"}]},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-023-00507-3","URL":"https:\/\/doi.org\/10.1007\/s40120-023-00507-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}